Remepy, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Remepy, Inc. - overview
Established
2022
Location
Ramat Gan, -, Israel
Primary Industry
Biotechnology
About
Founded in 2022 by co-founders Or Shoval and Michal Tsur and based in Ramat Gan, Israel, Remepy, Inc. offers hybrid drugs that combine digital molecule software for neuro-endocrine and neuro-immunological systems. In May 2024, Remepy, Inc. raised USD 10 million in seed funding led by investor NFX, with participation from other investors Vine Ventures, PsyMed Ventures, and Firstime Ventures.
TechAviv, Supernode Ventures, Fresh. fund, Samsung Next Ventures, StageNext, and 97212 Ventures. Remepy's core product is a hybrid drug, a pharmaceutical drug targeting a specific medical condition. Additionally, the company also offers an app that features personalised, non-invasive cognitive, psychological, and behavioural exercises.
The exercises include memory challenges, spatial navigation tasks, or mindfulness exercises, all tailored to the specific drug and the patient's condition. The app functions as a digital treatment protocol, providing patients with daily interventions and tracking their progress. It also gathers feedback and activity data, allowing the app to adjust the programme based on the patient's needs and responses.
Current Investors
Samsung NEXT Ventures, Supernode Ventures, TechAviv
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Healthcare IT, Analytics & Performance Software, Medical Software
Website
www.remepy.com/
Verticals
Mobile Apps
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.